Anti-LAG-3 antibody treatment initiated after symptom onset extends survival in ALS model mice.
- DOI
- 10.1016/j.neures.2026.105119
- Published
- 2026 Sep 10
- Container
- Neuroscience research
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.neures.2026.105119,
title = {Anti-LAG-3 antibody treatment initiated after symptom onset extends survival in ALS model mice.},
author = {Morisaki Y and Nomura N and Matsuda M and Ohshima M and Fukuda R and Komine O and Okuda T and Yamanaka K and Misawa H},
year = {2026},
journal = {Neuroscience research},
doi = {10.1016/j.neures.2026.105119},
url = {https://doi.org/10.1016/j.neures.2026.105119}
}RIS
TY - JOUR TI - Anti-LAG-3 antibody treatment initiated after symptom onset extends survival in ALS model mice. AU - Morisaki Y AU - Nomura N AU - Matsuda M AU - Ohshima M AU - Fukuda R AU - Komine O AU - Okuda T AU - Yamanaka K AU - Misawa H PY - 2026 JO - Neuroscience research DO - 10.1016/j.neures.2026.105119 UR - https://doi.org/10.1016/j.neures.2026.105119 ER -
APA
Y, M., N, N., M, M., M, O., R, F., O, K., T, O., K, Y., & H, M. (2026). Anti-LAG-3 antibody treatment initiated after symptom onset extends survival in ALS model mice.. Neuroscience research. https://doi.org/10.1016/j.neures.2026.105119
Source records
- pubmed · retrieved 2026-09-25T16:29:02.530Z